Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Paxalisib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 122,115Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Kazia’s Paxalisib Combo Shows 86% Tumor Drop in Metastatic TNBC
    Kazia’s Paxalisib Combo Shows 86% Tumor Drop in Metastatic TNBC

    02 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kazia-therapeutics-announces-86-reduction-in-tumor-burden-in-expanded-access-case-of-metastatic-tnbc-patient-treated-with-paxalisib-immunotherapy-regimen-302573460.html

    PR NEWSWIRE
    02 Oct 2025
    Share Share
    Kazia Paxalisib Disrupts Stage IV Breast Cancer Cells
    Kazia Paxalisib Disrupts Stage IV Breast Cancer Cells

    11 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kazia-therapeutics-reports-complete-ex-vivo-disruption-of-large-circulating-tumor-cell-clusters-in-stage-iv-her2-positive-breast-cancer-with-paxalisib-monotherapy-302553345.html

    PR NEWSWIRE
    11 Sep 2025
    Share Share
    Kazia Sees >50% Tumor Drop In Paxalisib Combo Trial
    Kazia Sees >50% Tumor Drop In Paxalisib Combo Trial

    09 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kazia-therapeutics-reports-early-efficacy-data-from-first-triple-negative-breast-cancer-patient-receiving-paxalisib-combination-regimen-achieving-50-reduction-in-circulating-tumor-cells-in-phase-1b-trial-302500778.html

    PR NEWSWIRE
    09 Jul 2025
    Share Share
    Kazia Therapeutics Updates on Recent Progress and Business
    Kazia Therapeutics Updates on Recent Progress and Business

    15 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kazia-therapeutics-highlights-recent-progress-and-provides-business-update-302456503.html

    PR NEWSWIRE
    15 May 2025
    Share Share
    Kazia Launches Paxalisib Immunotherapy Trial In Breast Cancer
    Kazia Launches Paxalisib Immunotherapy Trial In Breast Cancer

    30 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kazia-therapeutics-announces-the-launch-of-a-groundbreaking-trial-with-paxalisib-in-combination-with-immunotherapy-in-women-with-advanced-breast-cancer-302364230.html

    PR NEWSWIRE
    30 Jan 2025
    Share Share
    Kazia Therapeutics Updates Paxalisib Regulatory Pathway
    Kazia Therapeutics Updates Paxalisib Regulatory Pathway

    31 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kazia-therapeutics-provides-update-on-paxalisib-regulatory-pathway-following-type-c-meeting-with-fda-302340490.html

    PR NEWSWIRE
    31 Dec 2024
    Share Share